A Unique Healthcare Play

Featuring Louis Llanes

Louis Llanes, Founder Of Wealthnet Investments, is betting on healthcare R&D firm IQVIA. He discusses his trade idea in this interview with Justine Underhill. Filmed on May 3, 2018.

Published on
10 May, 2018
Micro, Trading
8 minutes
Asset class


  • SS

    Sophocles S.

    17 5 2018 08:02

    2       0

    Bring in more people like Louis!

    • LL

      Louis L.

      25 5 2018 01:13

      0       0

      Thank you! I’ll do my best to bring good ideas our team thinks will make money.

  • SH

    Syed H.

    13 5 2018 18:33

    1       0

    Great interview Justine. Keep it up.

  • JW

    John W.

    12 5 2018 11:39

    2       0

    Hey Louis, great analysis - I love your use of VWAP. These in-depth reviews are what I am here to see, and you are quickly becoming one of my favorites to watch here on RV. Side note - Quintiles was right here in my back yard in Cary NC.

    • LL

      Louis L.

      14 5 2018 20:05

      1       0

      Thank you

  • MS

    Michele S.

    11 5 2018 14:35

    1       0

    As a fellow interviewee, I enjoyed your analysis (and pick)-I only wish I had seen it early yesterday for an entry around 99-up over $3.50 in a day-nevertheless, you are now on my radar.

  • KF

    Karen F.

    11 5 2018 12:03

    0       0

    In my point of view too much goodwill and debt on the balancesheet. Certainly for an outsource company.

    • LL

      Louis L.

      11 5 2018 13:47

      2       0

      Goodwill is from merger. What’s more important is valuation on cash flows, not historical based book values which have less relationship to the valuation of the enterprise. This is not a company you would value based on net tangible book value in our view. That’d be appropriate for an asset rich company with little to no growth in cash flows.

  • GS

    Geoff S.

    10 5 2018 19:39

    5       0

    Interesting idea. Would love to hear more about the merger and how it has created the perceived competitive advantage. Also no word on valuation, unfortunately. It would be great if RV could capture those angles in its line of questioning with the money managers. Far more useful than stop loss/target prices, etc., which are less relevant to longer term investors.

    • EF

      Eric F.

      11 5 2018 00:10

      10       0

      To be fair, it’s trade ideas so if something catches your interest you can do the research / due diligence required.

    • ML

      Michael L.

      13 5 2018 01:05

      0       0

      Agree, especially since he mentioned competitive advantage a few times, he really should have spent 10 seconds talking about what those are. Just citing a high level theme like "increased R&D spending" and show some charts is not analysis. No mention of growth potential, upside to earnings...etc. Some of the luminaries that RV interviewed - Bass, Hempton, Cohodes..etc would totally tear this apart

    • LL

      Louis L.

      14 5 2018 03:36

      5       0

      The format of this is fast. The competence advantages comes from technology and databases from the merger that allows IQV to deliver outsourced R&D quicker and more effectively with Phase 2-4 trials. This has led to sticky Client relationships. Their customers have switching costs to go elsewhere or take it on internally. I alluded to this in presentation. Hope you keep watching and I’ll keep that in mind for you in later recordings.